📊 Get daily AI-graded market briefings
Morning + evening · AI impact + sector exposure · Free
LAST 30 DAYS
2 articles
AVG GRADE
HIGH
score: 0.50
SENTIMENT
BEARISH
TOTAL VIEWS
3
BEAM Latest News & AI Sentiment Analysis
2 articles · Grade: HIGH · Real-time AI-graded coverage
RECENT COVERAGE · 3 ARTICLES
Prime Medicine Announces Positive Resolution to Arbitration with Beam Therapeutics
Prime Medicine secured an arbitration tribunal victory establishing clear rights to develop PM647, a therapeutic candidate targeting...
Beam Therapeutics: A Better Entry Point Is Likely Coming (Rating Downgrade) (NASDAQ:BEAM)
Beam Therapeutics (BEAM) faces a valuation reset as analyst sentiment shifts toward caution despite positive pipeline developments. The...
Is Beam Therapeutics Inc. (BEAM) One of the Best Genomics Stocks to Buy According to Analysts?
Beam Therapeutics (BEAM) disclosed updated clinical trial data for its BEAM-302 candidate targeting alpha-1 antitrypsin deficiency at a...
E
ESEN Analytics
AI-powered equity research platform covering 5,000+ US equities. Our proprietary AI grading system (A+ to D scale) analyzes fundamentals, technicals, and news sentiment daily. Coverage data updated every 24 hours.
Learn about our methodology →
ⓘ AI-graded news coverage · Not investment advice